N-Acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine release, protease activity, and nuclear factor-kappaB deoxyribonucleic acid-binding activity in human fetal membranes in vitro.
The production of reactive oxygen species (ROS), prostaglandins (PGs), proinflammatory cytokines, and proteases has been implicated in the pathogenesis of term and preterm labor. The nuclear factor-kappaB (NF-kappaB) transcription pathway is activated by ROS and is a key regulator of PGs, proinflammatory cytokine release, and protease activity. N-Acetyl-cysteine (NAC) is an antioxidant that through its ability to scavenger ROS suppresses NF-kappaB DNA-binding activity and resultant gene expression. The aim of this study was to elucidate the effect of NAC on NF-kappaB DNA-binding activity, phospholipid metabolism, cytokine release, and protease activity from human fetal membranes. Human amnion and choriodecidua (n = 9 separate placentas) were treated with 0 (control), 5, 10, or 15 mM NAC in the presence of 10 micro g/ml lipopolysaccharide. After 6-h incubation, the tissues were collected, NF-kappaB DNA binding activity was assessed by gel shift binding assays, and matrix metalloproteinase-9 and urokinase-type plasminogen activator activity were determined by zymography. The incubation medium was collected and assayed for type II phospholipase A(2) tissue content, IL-6, IL-8, TNFalpha, and 8-isoprostane release by ELISA. The release of PGF(2alpha) was measured by RIA. Treatment of fetal membranes with NAC significantly suppressed lipopolysaccharide-stimulated type II phospholipase A(2) release and content; PGF(2alpha), IL-6, IL-8, TNFalpha, and 8-isoprostane release; and matrix metalloproteinase-9 and urokinase-type plasminogen activator enzyme activity and suppressed NF-kappaB DNA-binding activity (by ANOVA, P < 0.05). The data presented in this study demonstrate that NAC inhibits an NF-kappaB-activated pathway and subsequent phospholipid metabolism, proinflammatory cytokine release, and protease activity in human fetal membranes.
Lappas
Martha
M
Department of Obstetrics and Gynecology, University of Melbourne, and Mercy Perinatal Research Center, Mercy Hospital for Women, East Melbourne, 3002 Victoria, Australia. mlappas@unimelb.edu.au
Permezel
Michael
M
Rice
Gregory E
GE
D000111:Acetylcysteine / Q000494:pharmacology*; D000650:Amnion / Q000187:drug effects / Q000378:metabolism; D002823:Chorion / Q000187:drug effects / Q000378:metabolism; D046508:Culture Techniques; D016207:Cytokines / Q000378:metabolism*; D004247:DNA / Q000378:metabolism; D003656:Decidua / Q000187:drug effects / Q000378:metabolism; D015237:Dinoprost / Q000378:metabolism / Q000031:analogs & derivatives; D010450:Endopeptidases / Q000378:metabolism*; D005321:Extraembryonic Membranes / Q000187:drug effects* / Q000378:metabolism; D028441:F2-Isoprostanes / Q000378:metabolism; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D018384:Oxidative Stress; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D011247:Pregnancy; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
D016207:Cytokines; D028441:F2-Isoprostanes; D015850:Interleukin-6; D016209:Interleukin-8; D016328:NF-kappa B; D010743:Phospholipids; C075750:8-epi-prostaglandin F2alpha; D004247:DNA; D015237:Dinoprost; D007770:L-Lactate Dehydrogenase; D010741:Phospholipases A; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator; D020780:Matrix Metalloproteinase 9; D000111:Acetylcysteine